Media headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.9701936508397 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Should You Be Holding Aurinia Pharmaceuticals Inc (AUPH) Right Now? (finance.yahoo.com)
- Beholding Stock-:- Verizon Communications Inc. (NYSE:VZ), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), L Brands … – Market Breaking Point (press release) (journalfinance.net)
- Aurinia Pharmaceuticals Inc (AUPH) Lowered to “Hold” at Vetr Inc. (americanbankingnews.com)
- Aurinia Pharmaceuticals Inc (AUPH) Expected to Announce Earnings of -$0.13 Per Share (americanbankingnews.com)
- Aurinia Pharmaceuticals Patent Analysis: An Interview With The COO (seekingalpha.com)
AUPH has been the subject of several analyst reports. HC Wainwright decreased their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 18th. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price for the company. in a research report on Monday, July 31st. Finally, Cantor Fitzgerald set a $14.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $9.71.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 4.40% on Tuesday, hitting $6.52. 728,569 shares of the stock were exchanged. The company has a 50-day moving average of $6.22 and a 200-day moving average of $6.62. Aurinia Pharmaceuticals has a 12 month low of $1.97 and a 12 month high of $10.54. The stock’s market cap is $544.32 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities analysts predict that Aurinia Pharmaceuticals will post ($1.00) EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/2886769/aurinia-pharmaceuticals-auph-earning-somewhat-favorable-press-coverage-analysis-finds.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.